{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:08:00Z","timestamp":1706792880802},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/maj.0b013e31827ad893","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T17:18:28Z","timestamp":1357838308000},"page":"497-500","source":"Crossref","is-referenced-by-count":6,"title":["Suppression of Primary Aldosteronism and Resistant Hypertension by the Peroxisome Proliferator-activated Receptor Gamma Agonist Pioglitazone"],"prefix":"10.1016","volume":"345","author":[{"given":"Yusuke","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisaku","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Shono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumio","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yasue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31827ad893_bb0010","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","article-title":"Task Force Committee on Primary Aldosteronism, the Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009","volume":"58","author":"Nishikawa","year":"2011","journal-title":"Endocr J"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0025","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","article-title":"Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation","volume":"121","author":"Kaul","year":"2010","journal-title":"Circulation"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0030","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1210\/jc.2004-1267","article-title":"German and Austrian Adrenal Network. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation","volume":"90","author":"Betz","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1541-7786.MCR-06-0278","article-title":"Effects of thiazolidinediones on differentiation, proliferation, and apoptosis","volume":"5","author":"Chou","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/JME-10-0088","article-title":"Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production","volume":"46","author":"Uruno","year":"2011","journal-title":"J Mol Endocrinol"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/HYPERTENSIONAHA.109.141655","article-title":"Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone","volume":"55","author":"Li","year":"2010","journal-title":"Hypertension"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0050","doi-asserted-by":"crossref","first-page":"9311","DOI":"10.1074\/jbc.R109.025031","article-title":"Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?","volume":"285","author":"Ketsawatsomkron","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/jcem-36-2-401","article-title":"Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma","volume":"36","author":"Ganguly","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0060","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1210\/jc.2011-0573","article-title":"Significance of adrenocorticotropin stimulation test in the diagnosis of an aldosterone-producing adenoma","volume":"96","author":"Sonoyama","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pcad.2009.12.004","article-title":"Aldosterone: role in the cardiometabolic syndrome and resistant hypertension","volume":"52","author":"Whaley-Connell","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0070","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajh.2011.245","article-title":"Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension","volume":"25","author":"Shibata","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0075","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1210\/jc.2009-2010","article-title":"Adrenocortical zonation in humans under normal and pathological conditions","volume":"95","author":"Nishimoto","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0080","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/en.2011-1205","article-title":"Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem\/progenitor cell markers","volume":"152","author":"Boulkroun","year":"2011","journal-title":"Endocrinology"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2010.11.014","article-title":"The Wnt\/beta-catenin pathway in adrenocortical development and cancer","volume":"332","author":"El Wakil","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2011.12.006","article-title":"Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma","volume":"351","author":"Simon","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0100","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1128\/MCB.00441-06","article-title":"Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin","volume":"26","author":"Liu","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1097\/MAJ.0b013e31827ad893_bb0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejphar.2010.03.010","article-title":"Repression of beta-catenin signaling by PPAR gamma ligands","volume":"636","author":"Lu","year":"2010","journal-title":"Eur J Pharmacol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915306431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915306431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T15:50:47Z","timestamp":1539964247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915306431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0002962915306431"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31827ad893","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}